Shots:

• Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner
• As per collaboration agreements- Voyager has received an upfront payment to perform research and preclinical development of vectorized Abs directed against tau and alpha-synuclein in AD & PD respectively
• Voyager is not obligated to repay the upfront payment it received from AbbVie in connection with the Tau & ASN agreement but is no longer eligible to receive option payments- milestone payments- or royalties thereunder

- ­ Ref: Voyager | Image: abbvie